Literature DB >> 7699323

The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor.

S C Peiper1, Z X Wang, K Neote, A W Martin, H J Showell, M J Conklyn, K Ogborne, T J Hadley, Z H Lu, J Hesselgesser, R Horuk.   

Abstract

The Duffy antigen/receptor for chemokines (DARC), first identified on erythrocytes, functions not only as a promiscuous chemokine receptor but also as a receptor for the malarial parasite, Plasmodium vivax. The recent finding that DARC is ubiquitously expressed by endothelial cells lining postcapillary venules provides a possible insight into the function of this receptor because this anatomic site is an active interface for leukocyte trafficking. However, the biological significance of DARC is questionable since it has not yet been determined whether individuals lacking the expression of this protein on their erythrocytes (Duffy negative individuals), who are apparently immunologically normal, express the receptor on endothelial cells. However, we report here that DARC is indeed expressed in endothelial cells lining postcapillary venules and splenic sinusoids in individuals who lack the erythrocyte receptor. These findings are based on immunohistochemical, biochemical, and molecular biological analysis of tissues from Duffy negative individuals. We also present data showing that, in contrast to erythrocyte DARC, cells transfected with DARC internalize radiolabeled ligand. We conclude that the DARC may play a critical role in mediating the effects of proinflammatory chemokines on the interactions between leukocyte and endothelial cells since the molecular pathology of the Duffy negative genotype maintains expression on the latter cell type.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7699323      PMCID: PMC2191961          DOI: 10.1084/jem.181.4.1311

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Endothelial and leukocyte forms of IL-8. Conversion by thrombin and interactions with neutrophils.

Authors:  C A Hébert; F W Luscinskas; J M Kiely; E A Luis; W C Darbonne; G L Bennett; C C Liu; M S Obin; M A Gimbrone; J B Baker
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

2.  Structure and functional expression of a human interleukin-8 receptor.

Authors:  W E Holmes; J Lee; W J Kuang; G C Rice; W I Wood
Journal:  Science       Date:  1991-09-13       Impact factor: 47.728

3.  A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor.

Authors:  R Horuk; C E Chitnis; W C Darbonne; T J Colby; A Rybicki; T J Hadley; L H Miller
Journal:  Science       Date:  1993-08-27       Impact factor: 47.728

4.  Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells.

Authors:  K Neote; W Darbonne; J Ogez; R Horuk; T J Schall
Journal:  J Biol Chem       Date:  1993-06-15       Impact factor: 5.157

5.  The human erythrocyte inflammatory peptide (chemokine) receptor. Biochemical characterization, solubilization, and development of a binding assay for the soluble receptor.

Authors:  R Horuk; T J Colby; W C Darbonne; T J Schall; K Neote
Journal:  Biochemistry       Date:  1993-06-08       Impact factor: 3.162

6.  Cloning of complementary DNA encoding a functional human interleukin-8 receptor.

Authors:  P M Murphy; H L Tiffany
Journal:  Science       Date:  1991-09-13       Impact factor: 47.728

Review 7.  Properties of the novel proinflammatory supergene "intercrine" cytokine family.

Authors:  J J Oppenheim; C O Zachariae; N Mukaida; K Matsushima
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

8.  An isoform-specific mutation in the protein 4.1 gene results in hereditary elliptocytosis and complete deficiency of protein 4.1 in erythrocytes but not in nonerythroid cells.

Authors:  J G Conboy; J A Chasis; R Winardi; G Tchernia; Y W Kan; N Mohandas
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

9.  Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor.

Authors:  K Neote; D DiGregorio; J Y Mak; R Horuk; T J Schall
Journal:  Cell       Date:  1993-02-12       Impact factor: 41.582

10.  A new human Duffy blood group specificity defined by a murine monoclonal antibody. Immunogenetics and association with susceptibility to Plasmodium vivax.

Authors:  M E Nichols; P Rubinstein; J Barnwell; S Rodriguez de Cordoba; R E Rosenfield
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

View more
  73 in total

1.  A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines.

Authors:  Dorota Smolarek; Claude Hattab; Gholamreza Hassanzadeh-Ghassabeh; Sylvie Cochet; Carlos Gutiérrez; Alexandre G de Brevern; Rachanee Udomsangpetch; Julien Picot; Magdalena Grodecka; Kazimiera Wasniowska; Serge Muyldermans; Yves Colin; Caroline Le Van Kim; Marcin Czerwinski; Olivier Bertrand
Journal:  Cell Mol Life Sci       Date:  2010-05-11       Impact factor: 9.261

2.  Heterogeneity of endothelial cells: the specialized phenotype of human high endothelial venules characterized by suppression subtractive hybridization.

Authors:  J P Girard; E S Baekkevold; T Yamanaka; G Haraldsen; P Brandtzaeg; F Amalric
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation.

Authors:  Janet S Lee; Mark M Wurfel; Gustavo Matute-Bello; Charles W Frevert; Matthew R Rosengart; Mrunalini Ranganathan; Venus W Wong; Tarah Holden; Steve Sutlief; Ann Richmond; Stephen Peiper; Thomas R Martin
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

4.  Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.

Authors:  Michelle L Varney; Seema Singh; Aihua Li; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Cancer Lett       Date:  2010-10-29       Impact factor: 8.679

Review 5.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

6.  Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.

Authors:  Xiao-Hua Zeng; Zhou-Luo Ou; Ke-Da Yu; Lan-Yun Feng; Wen-Jing Yin; Jing Li; Zhen-Zhou Shen; Zhi-Min Shao
Journal:  Med Oncol       Date:  2014-08-06       Impact factor: 3.064

Review 7.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

8.  Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo.

Authors:  Janet S Lee; Charles W Frevert; Mark M Wurfel; Stephen C Peiper; Venus A Wong; Kimberley K Ballman; John T Ruzinski; Johng S Rhim; Thomas R Martin; Richard B Goodman
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

9.  Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Authors:  Seema Singh; Anguraj Sadanandam; Kalyan C Nannuru; Michelle L Varney; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

10.  Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection.

Authors:  M A Billstrom; G L Johnson; N J Avdi; G S Worthen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.